Insight Molecular Diagnostics (IMDX) EBITDA (2015 - 2026)

Insight Molecular Diagnostics has disclosed EBITDA across 12 years of filings, most recently posting -$4.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$4.4 million, up 35.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 20.54% YoY), and the FY2025 annual result was -$10.5 million, up 17.21% from the prior year.
• EBITDA came in at -$4.4 million for Q1 2026 at Insight Molecular Diagnostics, down from $17.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $17.1 million in Q4 2025 to a low of -$16.2 million in Q4 2023.
• The 5-year median for EBITDA is -$6.5 million (2023), against an average of -$4.2 million.
• Peak annual rise in EBITDA reached 293.9% in 2023, while the deepest fall reached 410.09% in 2023.
• Insight Molecular Diagnostics' EBITDA stood at -$11.6 million in 2022, then sank by 38.9% to -$16.2 million in 2023, then surged by 190.7% to $14.7 million in 2024, then advanced by 16.81% to $17.1 million in 2025, then tumbled by 125.74% to -$4.4 million in 2026.
• The last three EBITDA figures came in at -$4.4 million (Q1 2026), $17.1 million (Q4 2025), and -$11.0 million (Q3 2025), per Business Quant data.